Matt is responsible for leading trial unit teams conducting research in prostate cancer and osteosarcoma and leading the unit's Trial Conduct Methodology activities. For prostate cancer, recent activities have included STAMPEDE, a large randomised clinical trial successfully putting novel multi-arm multi-stage methods into practice and which has recently re-defined care for men with high-risk prostate cancer; RADICALS, an efficient, international trial asking many questions for men early prostate cancer; and RT01 and PR07 which have changed radiotherapy practices in the UK. For osteosarcoma, attention has focused on leading the central trials unit for EURAMOS-1 which is the largest RCT conducted in this rare disease, thanks to an extensive international collaboration and has defined the standard-of-care.
Matt has gathered a broad range of experience in clinical trials since joining the MRC (first at the Cancer Trials Office in Cambridge) back in 1995, and moving with the unit to UCL in 2013. Within the CTU, Matt chairs the Unit’s Protocol Review Committee, led the development of a new template protocol for clinical trials and is a member of the organising committee for the Unit’s series of Monday Lunchtime Seminars. Externally, Matt is a member of the NCRI Prostate Cancer Clinical Studies Group (CSG) and the Bone Subgroup of the NCRI Sarcoma CSG. He recently completed 5 years on Cancer Research UK’s main clinical trials funding body and previously spent seven years serving on a Research Ethics Committee. He reviews grant applications and articles for a wide range of funding bodies and journals. He has served on the faculty for clinical trials and statistic courses, including the EORTC's Statistics for Non-statisticians, ECCO-AACR-EORTC-ESMO's ("Flims") Workshop on Methods in Clinical Cancer Research, and ASCO's International Clinical Trials Workshop. Matt lectures on the UCL Institute of Clinical Trials and Methodology's MSc in Clinical Trials.
Matt has a particularinterest in improving clinical trial conduct, particularly of adaptive, platform trials, and trial reporting. He was involved in the DAMOCLES project which set standards for (independent) Data Monitoring Committees and led to the widespread use of charters for trial committees. He is part of the faculty for UCL's regular 1-day course on Data Monitoring Committees in practice. Matt served as a member of many IDMCs, attending more than 100 meetings.
Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396-408.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley
DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to
first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival
results from an adaptive, multiarm, multistage, platform randomised controlled
trial. Lancet. 2016;387(10024):1163-77.
Sydes MR, Johnson AL, Meredith SK, Rauchenberger
M, South A, Parmar MK. Sharing data from clinical trials: the rationale for a
controlled access approach. Trials. 2015;16(1):104.
Bielack SS, Smeland S, Whelan JS, Marina N,
Jovic G, Hook JM, et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus
Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With
Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative
MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
J Clin Oncol. 2015;33(20):2279-87.
Parmar MK, Carpenter J, Sydes MR. More multiarm
randomised trials of superiority are needed. Lancet. 2014;384(9940):283-4.
list of publications at UCL’s IRIS system